AbClon
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
AbClon is a South Korean biotech company that develops antibody-based medicines, drugs that use proteins engineered to target and block disease-causing molecules, focused on cancers such as stomach and breast cancer.
Its therapies are designed for use by patients and are developed in partnership with research networks including Swedish scientific groups. Listed on KOSDAQ, Korea's tech-focused small-cap exchange, AbClon operates primarily as an intellectual-property licensing business, having transferred the rights to its lead antibody candidate to a partner for clinical development.
Summary is AI-generated and may contain errors · figures from DART filings
AbClon was co-founded by Korean and Swedish scientist groups, and its research network includes Atlas Therapeutics AB, Affibody AB, and Alligator Bioscience AB in Sweden.
AbClon in five facts
What does AbClon do?
AbClon is a South Korean biotech company that develops antibody-based medicines, drugs that use proteins engineered to target and block disease-causing molecules, focused on cancers such as stomach and breast cancer.
Where is AbClon listed and in which sector?
AbClon (Korean name: 앱클론) trades under KRX code 174900 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is AbClon?
Its market capitalisation was US$356.1M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were AbClon's latest annual revenue and operating profit?
For fiscal year 2025, AbClon reported revenue of US$3.6M, an operating loss of US$13.3M and a net loss of US$13.5M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 101.5% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- [Amended] Supply contract signed (voluntary)
AbClon updated a previously disclosed supply contract, now worth US$313K, about 9% of its recent annual revenue, running through Nov 2026.
Supply contract · Sep 30 · 3 versions - [Amended] Supply contract signed (voluntary)
AbClon updated a previously disclosed supply contract, now worth US$260K, about 7.5% of its recent annual revenue, running through Oct 2026.
Supply contract · Aug 31 · 4 versions - Supply contract signed
AbClon disclosed a supply contract, worth US$577K, about 17.5% of its recent annual revenue, running through Dec 2026.
Supply contract · Aug 4 - [Amended] Supply contract signed
AbClon updated a previously disclosed supply contract, now worth US$527K, about 33.3% of its recent annual revenue, running through Jul 2026.
Supply contract · Jul 22 · 3 versions - Change of 30% or more in revenue or profit/loss structure (15% for large companies)Earnings · Jan 30